Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP issued a shareholder alert regarding Supernus Pharmaceuticals, investigating the board's conduct related to the recently announced acquisition by Indivior Pharmaceuticals. The law firm is examining whether the transaction offers a fair price, noting the exchange ratio of 1.5401 Indivior shares per Supernus share and a resulting 56.5%/43.5% ownership split.
Key figures
- Exchange ratio
- 1.5401
- Ownership split indivior
- 56.5%
- Ownership split supernus
- 43.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.